A Study Evaluating the Efficacy and Safety of Sildenafil in Patients With Erectile Dysfunction Receiving Hemodialysis

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 31, 2002

Study Completion Date

April 30, 2005

Conditions
Erectile DisfunctionHemodialysis
Interventions
DRUG

placebo

Placebo comparator to be given per protocol.

DRUG

sildenafil

oral sildenafil citrate at an initial dose of 25 mg, which could have been up-titrated to 50 mg at Visit 3 based on the patient's efficacy, safety and tolerability responses; at Visits 4 and 5, the dose could remain the same, be increased to 100 mg, or decreased to 25 mg depending on the safety, efficacy, and tolerability

Trial Locations (8)

60430-370

Pfizer Investigational Site, Fortaleza

30150-260

Pfizer Investigational Site, Belo Horizonte

Unknown

Pfizer Investigational Site, Belo Horizonte

Pfizer Investigational Site, São José do Rio Preto

86010-010

Pfizer Investigational Site, Londrina

17210-080

Pfizer Investigational Site, Jaú

18030-205

Pfizer Investigational Site, Sorocaba

01323-001

Pfizer Investigational Site, São Paulo

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00654017 - A Study Evaluating the Efficacy and Safety of Sildenafil in Patients With Erectile Dysfunction Receiving Hemodialysis | Biotech Hunter | Biotech Hunter